|
|
| (172 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | + | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | + | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32335367|t=ä. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response |pdf=|usr=}}
| + | *'''[[Clinical guidelines and advice]]''' |
| | + | |
| | + | |
| | + | |
| | + | *'''[[Respiration mgmt]]''' |
| | + | |
| | + | *'''[[Diagnosis (Laboratory)]]''' |
| | + | |
| | + | |
| | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | + | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | + | |
| | + | |
| | | | |
| − | *'''[[Research tools]]'''
| |
| − | {{tp|p=32142596|t=2020. Machine Learning, COVID?19 (2019?nCoV), and multi?OMICS |pdf=|usr=}}
| |
| − | {{tp|p=32187834|t=2020. ..COVID19: Cytometry and the New Challenge for Global Health |pdf=|usr=}}
| |
| | | | |
| − | *
| |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| | | | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32220422|t=2020. The hosts angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| − | {{tp|p=32271376|t=ä. Factors associated with prolonged viral RNA shedding in patients with COVID-19 |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Innate sensing]]''' | | *'''[[Innate sensing]]''' |
| − | *'''[[Immunology]]'''
| |
| − | {{tp|p=32348472|t=ä. A Marker of Systemic Inflammation or Direct Cardiac Injury: Should Cardiac Troponin Levels be Monitored in COVID-19 Patients?|pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Immunology]]''' |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| Zeile 29: |
Zeile 39: |
| | | | |
| | | | |
| − | *'''[[Microvascular]]''' | + | *'''[[Pathobiology]]''' |
| − | *
| + | |
| − | *'''[[Early symptoms]]'''
| + | |
| − | *'''[[Systemic disease, any manifestations]]'''
| + | |
| − | {{tp|p=32160148|t=2020. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32343223|t=2020. Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient |pdf=|usr=}}
| + | |
| − | {{tp|p=32298228|t=2020. Panton-Valentine Leukocidin-Secreting Staphylococcus aureus Pneumonia Complicating COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | + | *'''[[Disease Models]]''' |
| | | | |
| − | *'''[[ARDS]]'''
| |
| | | | |
| − | *'''[[Pulmonary embolism, coagulation]]''' | + | *'''[[Similar diseases and pathomechanisms]]''' |
| − | {{tp|p=32334995|t=2020. Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32303472|t=ä. Acute pulmonary embolism in a patient with COVID-19 pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32348233|t=2020. Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32227120|t=ä. Acute pulmonary embolism and COVID-19 pneumonia: a random association?|pdf=|usr=}}
| + | |
| − | {{tp|p=32338707|t=ä. Acute pulmonary embolism in conjunction with intramural right ventricular thrombus in a SARS-CoV-2-positive patient |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Hematology]]'''
| |
| − | *'''[[Heart]]'''
| |
| − | {{tp|p=32363381|t=ä. Does SARS-CoV-2 cause viral myocarditis in COVID-19 patients?|pdf=|usr=}}
| |
| − | {{tp|p=32227076|t=ä. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32196087|t=ä. SARS-CoV2: should inhibitors of the renin?angiotensin system be withdrawn in patients with COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32267502|t=ä. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection |pdf=|usr=}}
| |
| − | {{tp|p=32267494|t=ä. CAPACITY-COVID: a European registry to determine the role of cardiovascular disease in the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32285920|t=ä. Transient complete heart block in a patient with critical COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32285915|t=ä. Typical takotsubo syndrome triggered by SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32338706|t=ä. Myocarditis revealing COVID-19 infection in a young patient |pdf=|usr=}}
| |
| − | {{tp|p=32282027|t=ä. COVID-19-related myocarditis in a 21-year-old female patient |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Early symptoms]]''' |
| | | | |
| − | *'''[[Neurology, ophthalmology, orl]]''' | + | *'''[[Systemic disease, any manifestations]]''' |
| − | {{tp|p=32283980|t=2020. Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms |pdf=|usr=}}
| + | |
| − | {{tp|p=32269598|t=2020. Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say?|pdf=|usr=}}
| + | |
| − | {{tp|p=32370982|t=ä. Ensuring mental health care during the SARS-CoV-2 epidemic in France: a narrative review |pdf=|usr=}}
| + | |
| − | {{tp|p=32253535|t=ä. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study |pdf=|usr=}}
| + | |
| − | {{tp|p=32328771|t=ä. The role of self-reported olfactory and gustatory dysfunction as a screening criterion for suspected COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32303881|t=ä. Possible link between anosmia and COVID-19: sniffing out the truth |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[Dermatology]]''' | + | *'''[[Co-Infection]]''' |
| − | *'''[[Gastroenterology, hepatology]]'''
| + | |
| | | | |
| | | | |
| | + | *'''[[Pulmonary embolism, coagulation]]''' |
| | | | |
| − | *'''[[Kidney, urology]]==
| |
| − | {{tp|p=32299479|t=2020. Acute kidney injury in SARS-CoV-2 infected patients |pdf=|usr=}}
| |
| − | {{tp|p=32197060|t=2020. Rhabdomyolysis as Potential Late Complication Associated with COVID-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *
| |
| − | *'''[[Pathobiology]]'''
| |
| − | {{tp|p=32294179|t=ä. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications |pdf=|usr=}}
| |
| − | {{tp|p=32293672|t=ä. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Disease Models]]'''
| |
| − | {{tp|p=32215622|t=ä. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility |pdf=|usr=}}
| |
| − | {{tp|p=32378471|t=2020. Animal models for emerging coronavirus: progress and new insights |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Hematology]]''' |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]'''
| |
| − | {{tp|p=31859605|t=2020. Genetic manipulation of porcine deltacoronavirus reveals insights into NS6 and NS7 functions: a novel strategy for vaccine design |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *
| + | *'''[[Heart]]''' |
| − | *'''[[Diagnosis (Laboratory)]]''' | + | |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]'''
| + | |
| − | {{tp|p=32294704|t=ä. Structured thoracic computed tomography report for COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32374802|t=ä. The halo sign as a chest computed tomography finding of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32241244|t=2020. Diagnostic value and key features of computed tomography in Coronavirus Disease 2019 |pdf=|usr=}}
| + | |
| − | {{tp|p=32285222|t=ä. Three unsuspected CT diagnoses of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32285028|t=2020. Lung Changes on Chest CT During 2019 Novel Coronavirus (COVID-19) Pneumonia |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Neurology, ophthalmology, orl]]''' |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − | {{tp|p=32276598|t=2020. Using echocardiography to guide the treatment of novel coronavirus pneumonia |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Clinical guidelines and advice]]'''
| |
| − | {{tp|p=32306118|t=ä. COVID-19 in otolaryngologist practice: a review of current knowledge |pdf=|usr=}}
| |
| − | {{tp|p=32352517|t=ä. Anticoagulation in COVID-19 |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Dermatology]]''' |
| | | | |
| − | *'''[[Respiration mgmt]]'''
| |
| − | {{tp|p=32371555|t=2020. Utility of extracorporeal membrane oxygenation in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32357995|t=2020. Tracheal intubation in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32326959|t=2020. High-flow nasal cannula may be no safer than non-invasive positive pressure ventilation for COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=C7156900|t=2020. Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series |pdf=|usr=}}
| |
| − | {{tp|p=32322959|t=ä. Tracheostomy in the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32314050|t=ä. Recommendation of a practical guideline for safe tracheostomy during the COVID-19 pandemic |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Gastroenterology, hepatology]]''' |
| | + | |
| | + | *'''[[Kidney, urology]]''' |
| | + | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| − | {{tp|p=32232395|t=ä. Initial COVID-19 affecting cardiac patients in China |pdf=|usr=}}
| + | |
| − | {{tp|p=32324223|t=ä. Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence |pdf=|usr=}}
| + | |
| − | {{tp|p=32324222|t=ä. Switching to another antihypertensive effective drug when using ACEIs/ARBs to treat arterial hypertension during COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32236478|t=ä. Speculation is not evidence: antihypertensive therapy and COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32286607|t=ä. Might renin?angiotensin system blockers play a role in the COVID-19 pandemic?|pdf=|usr=}}
| + | |
| − | {{tp|p=32344292|t=2020. COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors |pdf=|usr=}}
| + | |
| − | {{tp|p=32305831|t=ä. Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Case reports]]''' | | *'''[[Case reports]]''' |
| − | {{tp|p=32241316|t=ä. Case Report on Early Diagnosis of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32343659|t=2020. A Moderate Case of COVID-19 Viral Pneumonia During the SARS-CoV-2 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32160149|t=2020. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel Coronavirus Disease, United States |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | | | |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32337324|t=2020. The Data set for Patient Information Based Algorithm to Predict Mortality Cause by COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32267826|t=2020. Clinical Characteristics of Patients Hospitalized with Coronavirus Disease, Thailand |pdf=|usr=}}
| |
| − | {{tp|p=32208917|t=2020. The different clinical characteristics of corona virus disease cases between children and their families in China ? the character of children with COVID-19 |pdf=|usr=}}
| |
| | | | |
| | + | |
| | + | *'''[[Registries]]''' |
| | | | |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| − | {{tp|p=C7102592|t=ä. Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID) |pdf=|usr=}}
| |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32363880|t=2020. Medical treatment options for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32372695|t=2020. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol |pdf=|usr=}}
| |
| − | {{tp|p=32347925|t=ä. Statin therapy in COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32347923|t=ä. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety |pdf=|usr=}}
| |
| − | {{tp|p=32337546|t=ä. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?|pdf=|usr=}}
| |
| − | {{tp|p=32282032|t=ä. Neprilysin inhibitor?angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients |pdf=|usr=}}
| |
| | | | |
| | + | |
| | + | *'''[[Other routes of infection]]''' |
| | | | |
| | | | |
| − | *'''[[The morbid survivor]]'''
| |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| − | *'''[[Other routes of infection]]'''
| + | |
| − | {{tp|p=32241022|t=ä. SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32297915|t=ä. Comment of the potential risks of sexual and vertical transmission of Covid-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32243255|t=2020. Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations |pdf=|usr=}}
| + | |
| − | {{tp|p=32342724|t=2020. Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32324531|t=2020. The Practice of Wearing Surgical Masks during the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32284092|t=2020. Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 by WHO-Recommended Hand Rub Formulations and Alcohols |pdf=|usr=}}
| |
| − | {{tp|p=32282025|t=ä. Donning and doffing of personal protective equipment (PPE) for angiography during the COVID-19 crisis |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | *
| |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32228737|t=ä. COVID-19 disease emergency operational instructions for Mental Health Departments issued by the Italian Society of Epidemiological Psychiatry |pdf=|usr=}}
| |
| − | {{tp|p=32303485|t=ä. French consensus on management of head and neck cancer surgery during COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32338298|t=ä. The After Diagnosis Head and Neck cancer-specific Patient Concerns Inventory (HaNC-AD) as a pre-treatment preparation aid during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32232396|t=ä. Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32361812|t=ä. Mental health treatment online during the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32338764|t=ä. A treatment strategy for acute myocardial infarction and personal protection for medical staff during the COVID-19 epidemic: the Chinese experience |pdf=|usr=}}
| |
| − | {{tp|p=32286606|t=ä. Priorities for Cath labs in the COVID-19 tsunami: Roberto Ferrari and co-authors present a procedure to follow subsequent to the outbreak in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32320040|t=ä. Health system, public health, and economic implications of managing COVID-19 from a cardiovascular perspective |pdf=|usr=}}
| |
| − | {{tp|p=32242891|t=ä. COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel |pdf=|usr=}}
| |
| − | {{tp|p=32285027|t=2020. Breast Cancer Diagnosis, Treatment and Follow-Up During COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32285026|t=2020. Sars-CoV-2 (COVID-19) Outbreak and Breast Cancer Surgery in Turkey |pdf=|usr=}}
| |
| − | {{tp|p=32305011|t=2020. Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)?related disease pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32294611|t=2020. A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19?positive patients with cancer |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32342698|t=ä. Mental health care for medical staff and affiliated healthcare workers during the COVID-19 pandemic |pdf=|usr=}}
| |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32363492|t=ä. Prevalence and socio-demographic correlates of psychological health problems in Chinese adolescents during the outbreak of COVID-19 |pdf=|usr=}}
| + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| − | {{tp|p=32339092|t=2020. Decreased Influenza Incidence under COVID-19 Control Measures, Singapore |pdf=|usr=}}
| + | |
| − | {{tp|p=32339091|t=2020. Collateral Benefit of COVID-19 Control Measures on Influenza Activity, Taiwan |pdf=|usr=}}
| + | |
| − | {{tp|p=32297932|t=ä. Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage |pdf=|usr=}}
| + | |
| − | {{tp|p=32348457|t=ä. Where have the STEMIs gone during COVID-19 lockdown?|pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | *'''[[Educational aspects of the status hygienicus]]'''
| |
| − | *
| |
| − | *'''[[Host, vector, one health, atmospheric aspects]]'''
| |
| − | {{tp|p=C7151430|t=ä. Airborne transmission of SARS-CoV-2: the world should face the reality |pdf=|usr=}}
| |
| − | {{tp|p=32363409|t=2020. SARS-CoV-2 spread in Northern Italy: what about the pollution role?|pdf=|usr=}}
| |
| − | {{tp|p=32283458|t=2020. COVID-19 as a factor influencing air pollution?|pdf=|usr=}}
| |
| − | {{tp|p=32268945|t=ä. Can atmospheric pollution be considered a co-factor in extremely high level of SARS-CoV-2 lethality in Northern Italy?? |pdf=|usr=}}
| |
| − | {{tp|p=32361082|t=2020. Food safety issues related to wildlife have not been taken seriously from SARS to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32353790|t=2020. Biomass use and COVID-19: A novel concern |pdf=|usr=}}
| |
| − | {{tp|p=32330766|t=ä. Is temperature reducing the transmission of COVID-19 ?|pdf=|usr=}}
| |
| − | {{tp|p=32202420|t=ä. An Imperative Need for Research on the Role of Environmental Factors in Transmission of Novel Coronavirus (COVID-19) |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Educational aspects of the status hygienicus]]''' |
| | + | ---- |
| | | | |
| | | | |
| | + | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| − | {{tp|p=32315281|t=2020. Possible Bat Origin of Severe Acute Respiratory Syndrome Coronavirus 2 |pdf=|usr=}}
| |
| − | {{tp|p=32315626|t=2020. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32148173|t=2020. Is SARS-CoV-2 originated from laboratory? A rebuttal to the claim of formation via laboratory recombination |pdf=|usr=}}
| |
| − | {{tp|p=32102621|t=2020. No credible evidence supporting claims of the laboratory engineering of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32056509|t=2020. HIV-1 did not contribute to the 2019-nCoV genome |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Epidemiology]]''' |
| | | | |
| − | *'''[[Remission, recurrence and persistence]]'''
| |
| | | | |
| | | | |
| − | *'''[[Epidemiology]]'''
| |
| − | {{tp|p=32323978|t=ä. Letter to the Editor: Wastewater-Based Epidemiology Can Overcome Representativeness and Stigma Issues Related to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32202421|t=ä. Can a Paper-Based Device Trace COVID-19 Sources with Wastewater-Based Epidemiology?|pdf=|usr=}}
| |
| − | {{tp|p=32311865|t=2020. Prevention of exposure and dispersion of COVID-19 using air purifiers: challenges and concerns |pdf=|usr=}}
| |
| − | {{tp|p=32375455|t=2020. Prediction of COVID-19 transmission dynamics using a mathematical model considering behavior changes in Korea |pdf=|usr=}}
| |
| − | {{tp|p=32345002|t=2020. Joint Statement of the Korean Society for Preventive Medicine and the Korean Society of Epidemiology on the response to the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32345000|t=2020. Urgent appeal to minimize community health impacts of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32345001|t=2020. Recommendations to the government following the declaration of COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32344999|t=2020. Preparedness and response to community spread of COVID-19 governmental and national recommendations for COVID-19 by the Pan-Academic Action Committee |pdf=|usr=}}
| |
| − | {{tp|p=32344998|t=2020. Joint Statement of the Korean Society for Preventive Medicine and the Korean Society of Epidemiology on the response to the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32344997|t=2020. Professional academic organizations on infectious disease Joint Statement on COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32192278|t=2020. WHO International Health Regulations Emergency Committee for the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32164053|t=2020. Estimating the reproductive number and the outbreak size of COVID-19 in Korea |pdf=|usr=}}
| |
| − | {{tp|p=32035431|t=2020. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea |pdf=|usr=}}
| |
| − | {{tp|p=32023775|t=2020. An interim review of the epidemiological characteristics of 2019 novel coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32202489|t=ä. Risk of COVID-19 importation to the Pacific islands through global air travel |pdf=|usr=}}
| |
| − | {{tp|p=32100667|t=ä. Passengers destinations from China: low risk of Novel Coronavirus (2019-nCoV) transmission into Africa and South America |pdf=|usr=}}
| |
| − | {{tp|p=32242790|t=ä. The challenges and considerations of community-based preparedness at the onset of COVID-19 outbreak in Iran, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32373189|t=2020. Smoking Cessation as a Public Health Measure to Limit the Coronavirus Disease 2019 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32352515|t=ä. The battle against COVID-19: mortality in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32255475|t=ä. Denominator matters in estimating COVID-19 mortality rates |pdf=|usr=}}
| |
| − | {{tp|p=32255476|t=ä. COVID-19 experience in Bergamo, Italy |pdf=|usr=}}
| |
| − | {{tp|p=32255477|t=ä. Strategies to control COVID-19 and future pandemics in Africa and around the globe |pdf=|usr=}}
| |
| − | {{tp|p=32352314|t=2020. The COVID-19 epidemic, its mortality, and the role of non-pharmaceutical interventions |pdf=|usr=}}
| |
| − | {{tp|p=32347745|t=ä. Ethical aspects of the COVID-19 crisis: How to deal with an overwhelming shortage of acute beds |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Remission, recurrence and persistence]]''' |
| | | | |
| | | | |
| | + | |
| | + | *'''[[Failure of executive measures]]''' |
| | + | ---- |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − | {{tp|p=32246996|t=ä. The SARS-CoV-2 epidemic: how the Italian public is being informed |pdf=|usr=}}
| |
| − | {{tp|p=32292239|t=2020. Unpacking the black box: How to promote citizen engagement through government social media during the COVID-19 crisis |pdf=|usr=}}
| |
| − | {{tp|p=32252845|t=ä. Adaptation of the National Plan for the Prevention and Fight Against Pandemic Influenza to the 2020 COVID-19 Epidemic in France |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Failure of executive measures]]'''
| |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=C7152572|t=ä. Coronavirus Goes Viral: Quantifying the COVID-19 Misinformation Epidemic on Twitter |pdf=|usr=}}
| + | |
| − | {{tp|p=32241328|t=ä. Limited Early Warnings and Public Attention to Coronavirus Disease 2019 in China, January?February, 2020: A Longitudinal Cohort of Randomly Sampled Weibo Users |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| | + | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | + | ---- |
| | + | |
| | + | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | *'''[[Current state of coviki.org]]'''
| |
| − | *[[PubMed selected papers unsorted to be listed in contents topics]]
| |
| − | *[[coviki state of development]]
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32293675|t=ä. Key words to be adopted for COVID-19 research: A return to simple, large, randomized trials |pdf=|usr=}} | + | |
| | + | |
| | + | *'''[[Research tools]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| − | *[http://www.okaybio.com covid19 antibodies, proteins & reagents] | + | |
| − | *[http://www.reactionbiology.com 700 kinsse assays] | + | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
